苯妥英钠代谢受磺胺噻唑抑制的癫痫患者。
Inhibition of phenytoin metabolism by sulthiame in epileptic patients.
机构信息
Department of Clinical Pharmacology, St Bartholomew's Hospital, London.
出版信息
Br J Clin Pharmacol. 1974 Feb;1(1):59-66. doi: 10.1111/j.1365-2125.1974.tb00207.x.
Abstract
1 Measurements have been made of steady state serum phenytoin concentration, serum half-life of (14)C-labelled phenytoin, and the urinary ratio of the major metabolite of phenytoin to the unchanged drug (p-HPPH: DPH ratio) in epileptic patients on and off sulthiame therapy. 2 Starting sulthiame treatment produced an increase in serum phenytoin concentration, a prolongation of the half-life and an increase in the p-HPPH: DPH ratio. The total urinary output of phenytoin plus p-HPPH was unaltered by sulthiame. 3 The results indicate that sulthiame or one of its metabolites inhibits the parahydroxylation of phenytoin by hepatic enzymes.
摘要
我们对正在使用和停用氨苯砜治疗的癫痫患者的稳态血清苯妥英浓度、（14）C 标记的苯妥英的血清半衰期以及苯妥英的主要代谢物与未改变的药物的尿比值（p-HPPH:DPH 比值）进行了测量。
氨苯砜治疗开始后，血清苯妥英浓度增加，半衰期延长，p-HPPH:DPH 比值增加。氨苯砜治疗并未改变苯妥英加 p-HPPH 的总尿排出量。
结果表明，氨苯砜或其代谢物之一抑制了肝酶对苯妥英的对羟化作用。
相似文献
1
Inhibition of phenytoin metabolism by sulthiame in epileptic patients.苯妥英钠代谢受磺胺噻唑抑制的癫痫患者。
Br J Clin Pharmacol. 1974 Feb;1(1):59-66. doi: 10.1111/j.1365-2125.1974.tb00207.x.
2
Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients.不同稳态血清苯妥英浓度下癫痫患者示踪剂量苯妥英消除率。
Br J Clin Pharmacol. 1974 Apr;1(2):155-61. doi: 10.1111/j.1365-2125.1974.tb00225.x.
3
Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Ther Drug Monit. 1985;7(4):405-10. doi: 10.1097/00007691-198512000-00007.
4
Phenytoin metabolism in subjects with long and short plasma half-lives.血浆半衰期长短不同的受试者中苯妥英的代谢
Ther Drug Monit. 1982;4(3):281-92. doi: 10.1097/00007691-198208000-00006.
5
Phenytoin metabolism in mice.
Drug Metab Dispos. 1982 Mar-Apr;10(2):156-60.
6
Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.人类不同药物羟化表型中芳香族苯妥英羟化的立体化学
J Pharmacol Exp Ther. 1987 May;241(2):615-22.
7
Comparative drug elimination in man-diphenylhydantoin and amobarbital.人体内苯妥英钠和异戊巴比妥的药物消除比较
Eur J Clin Pharmacol. 1975 Oct 10;9(1):79-83. doi: 10.1007/BF00613433.
8
Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.苯妥英在人、猫和大鼠体内外代谢生成5-(4-羟苯基)-5-苯基乙内酰脲（HPPH）以及对苯妥英诱导的牙龈过度生长的易感性。
J Periodontal Res. 1999 Apr;34(3):145-53. doi: 10.1111/j.1600-0765.1999.tb02235.x.
9
Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin.苯妥英代谢物与人类血清白蛋白结合的生物相互作用色谱研究。
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 19;836(1-2):83-91. doi: 10.1016/j.jchromb.2006.03.043. Epub 2006 Apr 18.
10
Metabolism of diphenylhydantoin (phenytoin) during pregnancy.
Br J Obstet Gynaecol. 1979 Feb;86(2):125-32. doi: 10.1111/j.1471-0528.1979.tb10579.x.
引用本文的文献
1
Sulthiame monotherapy for epilepsy.硫喷妥钠单药治疗癫痫。
Cochrane Database Syst Rev. 2021 Sep 23;9(9):CD010062. doi: 10.1002/14651858.CD010062.pub3.
2
Sulthiame monotherapy for epilepsy.舒噻美单药治疗癫痫。
Cochrane Database Syst Rev. 2014 Mar 9;2014(3):CD010062. doi: 10.1002/14651858.CD010062.pub2.
3
Pharmacokinetic interactions with antiepileptic drugs.与抗癫痫药物的药代动力学相互作用。
Clin Pharmacokinet. 1982 Jan-Feb;7(1):57-84. doi: 10.2165/00003088-198207010-00004.
4
Drug interactions with phenytoin.与苯妥英钠的药物相互作用。
Drugs. 1981 Feb;21(2):120-37. doi: 10.2165/00003495-198121020-00003.
5
The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.抗心律失常药物在妊娠和哺乳期的药代动力学。
Clin Pharmacokinet. 1987 Apr;12(4):253-91. doi: 10.2165/00003088-198712040-00002.
6
Drug interactions that matter. A critical reappraisal.重要的药物相互作用。批判性重新评估。
Drugs. 1988 Jul;36(1):83-110. doi: 10.2165/00003495-198836010-00006.
7
Antiepileptic drug toxicity: definition and mechanism of action.抗癫痫药物毒性：定义与作用机制
Ital J Neurol Sci. 1986 Apr;7(2):209-22. doi: 10.1007/BF02230884.
8
Pharmacokinetic drug interactions with phenytoin (Part II).苯妥英的药代动力学药物相互作用（第二部分）。
Clin Pharmacokinet. 1990 Feb;18(2):131-50. doi: 10.2165/00003088-199018020-00004.
9
Drug interactions and clinical pharmacokinetics.药物相互作用与临床药代动力学。
Clin Pharmacokinet. 1976;1(5):351-72. doi: 10.2165/00003088-197601050-00003.
10
Clinical pharmacokinetics of phenytoin.苯妥英钠的临床药代动力学
Clin Pharmacokinet. 1979 May-Jun;4(3):153-69. doi: 10.2165/00003088-197904030-00001.
本文引用的文献
1
THE USE OF OSPOLOT IN THE TREATMENT OF EPILEPSY.OSPOLOT在癫痫治疗中的应用。
Epilepsia. 1964 Mar;5:68-73. doi: 10.1111/j.1528-1157.1964.tb04347.x.
2
Clinical trial of Ospolot in epilepsy.奥司波洛治疗癫痫的临床试验。
Dev Med Child Neurol. 1963 Jun;5:313-5.
3
Some causes of ineffectiveness of diphenylhydantoin.苯妥英钠无效的一些原因。
Arch Neurol. 1966 May;14(5):489-92. doi: 10.1001/archneur.1966.00470110033004.
4
The rate of decline of diphenylhydantoin in human plasma.人体血浆中苯妥英的下降速率。
Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121-34. doi: 10.1002/cpt1970111121.
5
Effect of dosage increments on blood phenytoin concentrations.剂量增加对血液中苯妥英浓度的影响。
J Neurol Neurosurg Psychiatry. 1972 Dec;35(6):873-6. doi: 10.1136/jnnp.35.6.873.
6
Drug--interaction between sulthiame (Ospolot (R)) and phenytoin in the treatment of epilepsy.药物——舒噻美（奥索波洛（注册商标））与苯妥英钠在癫痫治疗中的相互作用。
Dan Med Bull. 1969 May;16(5):154-8.
7
Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.舒噻美（奥司泊妥）作为二苯乙内酰脲代谢的抑制剂。
Epilepsia. 1968 Mar;9(1):17-22. doi: 10.1111/j.1528-1157.1968.tb04954.x.
8
Pharmacokinetic study of a patient with diphenylhydantoin toxicity.苯妥英钠中毒患者的药代动力学研究。
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):521-8. doi: 10.1002/cpt1973144part1521.
9
Proceedings: Inhibition of phenytoin metabolism by sulthiame.论文集：舒噻美对苯妥英代谢的抑制作用
Br J Pharmacol. 1973 Sep;49(1):157P-158P.
Zotero 插件